Weight-Loss Drugs Reveal the Body’s Astonishing Complexity
Scientists didn’t invent the
body’s GLP-1 signaling system.
They discovered how to use it.
Weight-Loss Drugs Reveal
the Body’s Astonishing Complexity
by Ronald D. Fritz, PhD
Weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have become household names. Millions of people are using these drugs, often with remarkable results. But how do they work? Why are scientists now investigating their possible effects on addiction, cancer, and even brain health? And what do these discoveries reveal about the extraordinary complexity of the human body?
A recent special issue of Science explores the expanding medical applications of these medications, presenting new research suggesting that their effects extend far beyond weight control.
GLP-1 and Beyond: Targeting Metabolism. (Science, special issue, 394:6824, 5 November 2026). This issue reviews the medications’ effectiveness, potential new applications, benefits, and risks.
An Extraordinary System Already Inside Us
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced primarily by specialized cells in the intestines when we eat. The new weight-loss medications are designed to mimic or enhance the effects of this natural hormone. Once released, GLP-1 sets in motion a remarkable series of precisely coordinated biological responses involving several organs throughout the body.
When food enters the digestive system, natural GLP-1 helps signal the pancreas to release insulin, allowing cells to absorb glucose from the bloodstream. Remarkably, this response depends on blood sugar levels, helping prevent excessive insulin release when glucose is low.
At the same time, GLP-1 also suppresses the release of glucagon, another pancreatic hormone that raises blood sugar. It also slows stomach emptying and helps communicate with the brain to regulate appetite and the sensation of fullness.
Complexity Within Cells
At the microscopic level, the coordination is equally astonishing. GLP-1 molecules must recognize and attach to precisely shaped receptors on specific cells, setting off a chain of chemical signals that helps regulate insulin release. And this process responds to changing blood sugar levels, automatically adjusting the body’s response as needed, 24/7. It’s like a sophisticated climate-control system that continuously monitors conditions and automatically adjusts heating and cooling to maintain a comfortable temperature—except the body’s system coordinates multiple organs and chemical signals simultaneously.
Consider what this requires. Specialized intestinal cells must detect nutrients and release chemical messengers. These messengers must reach and interact with specific receptors on distant cells, triggering coordinated responses involving digestion, blood sugar, and appetite.
This intricate coordination occurs repeatedly throughout every day, automatically adjusting to changing conditions, without a moment of conscious direction from us!
No wonder the psalmist David declared, “I am fearfully and wonderfully made: marvellous are thy works.” (Psalm 139:14, KJV).
CEH has previously highlighted other remarkable features of the digestive system revealing additional layers of biological coordination and regulation:
- “Pancreas Knows Not to Digest Itself” (April 24, 2022),
- “How the Vagus Nerve Regulates Digestion” (November 18, 2025),
- “Of All the Nerves, the Great Vagus Connects Everything” (September 1, 2026).
How Scientists Harnessed the GLP-1 System
The new weight-loss medications work by mimicking and enhancing the body’s natural hormonal signaling system.
Natural GLP-1 is rapidly broken down, typically within minutes. Scientists engineered medications that produce similar effects but remain active much longer, helping people feel less hungry, become satisfied with smaller meals, and ultimately consume fewer calories.
The results have been impressive.
Coordinated regulation by hormones at the cell and organ level keeps human weight normally under control.
Clinical trials have reported average weight reductions of approximately 15–21%, depending on the medication, dosage, and patient population. For someone weighing 250 pounds, that represents approximately 38–53 pounds!
These medications also improve blood sugar regulation, and some have demonstrated important cardiovascular and kidney benefits in specified patient populations.
But as the new Science special issue reveals, researchers are discovering that the effects of these medications may extend far beyond weight loss and blood sugar control.
Unexpected Connections to Addiction and Cancer
One of the most intriguing reports in the new Science special issue concerns addiction.
Researchers have observed that GLP-1 medications may reduce cravings not only for food but also for alcohol and certain addictive substances. Nora Volkow and Eric Wargo, discuss evidence that these drugs influence the brain’s reward pathways, including dopamine-related signaling. They suggest that understanding addiction may require considering interactions among the brain, metabolism, hormones, inflammation, and cardiovascular function.
In other words, a medication originally developed to help regulate blood sugar may also influence behaviors associated with addiction.
Another Science article, by Blánaid Hicks and Anton Pottegård, examines possible connections between GLP-1 medications and cancer risk. Some observational studies have suggested reduced risks for particular cancers among users. However, randomized clinical evidence has not yet established a general cancer-prevention benefit. The authors emphasize the need for more rigorous research.
Scientists are also investigating possible effects on cognition, aging, and Alzheimer’s disease, although the evidence remains preliminary.
Benefits, Risks, and Unanswered Questions
Despite their impressive effectiveness, GLP-1 medications are not without limitations.
Common side effects include nausea, vomiting, diarrhea, constipation, and other digestive disturbances. Less common but potentially serious problems include gallbladder disease, pancreatitis, and dehydration. Certain medications also carry warnings concerning thyroid tumors observed in laboratory rodents.
Another challenge is that patients frequently regain weight after discontinuing treatment. Maintaining the benefits may therefore require long-term medication, together with appropriate nutrition and physical activity.
The drugs are powerful, but their effects also reveal just how extensively the body’s regulatory systems are interconnected. Influencing one component can produce consequences across multiple organs and physiological processes.
The greatest marvel is not what scientists have invented. It is what they have discovered was already there.
What Does This Reveal About Design?
These discoveries reveal something even more remarkable than the medications themselves: scientists didn’t invent the body’s sophisticated, integrated systems for regulating appetite, digestion, and blood sugar.
They discovered how to harness them.
Consider what these systems entail. The natural GLP-1 signaling system requires specialized hormone-producing cells, precisely structured molecules, selective receptors, intricate signaling pathways, and coordinated responses involving multiple organs. Even more remarkable, these components must work together within an elaborate network of feedback mechanisms that continually adjust the body’s responses to changing conditions. The effectiveness of the entire system depends not simply on the existence of its individual components, but on their precise coordination. Without these essential regulatory mechanisms, the body could not maintain the physiological balance necessary to sustain life.
Such intricate and essential coordination raises a profound question: How did both the biological ‘hardware’—the specialized cells, hormones, and receptors—and the accompanying ‘software’—the signaling pathways and feedback mechanisms that govern their interactions—originate and become so seamlessly integrated?
The conventional evolutionary explanation invokes random mutations and natural selection to account for the origin of such biological complexity. Yet the extraordinary specificity, functional interdependence, and coordinated regulation exhibited by this system challenge the adequacy of unguided evolutionary processes to explain its origin. Such remarkable precision and integration point compellingly toward purposeful design rather than the undirected accumulation of genetic changes.
For further discussion of the challenges facing evolutionary explanations involving random mutations and natural selection, see these related CEH articles:
- “Do Mutations Provide New Genetic Information?” (July 5, 2022),
- “Cells Have a ‘Hail Mary’ Strategy to Minimize Damage” (June 2, 2026),
- “Design Crashes the LUCA Party” (April 22, 2026).
Modern medicine is making extraordinary progress by discovering ways to influence the body’s natural regulatory mechanisms. Yet the sophistication of those mechanisms represents an even greater achievement than the medications developed to exploit them.
The greatest marvel is not what scientists have invented. It is what they have discovered was already there.
References
- Science. (2026, November 5). GLP-1 and Beyond: Targeting Metabolism. Special issue, Volume 394, Issue 6824. AAAS overview of the special issue.
- Volkow, N., and Wargo, E. (2026). GLP-1 receptor agonists in addiction therapy. Science, Volume 394, Issue 6824.
- Hicks, B., and Pottegård, A. (2026). GLP-1 therapies and cancer risk. Science, Volume 394, Issue 6824.
- Blüher, M. (2026). Review of obesity pharmacotherapies. Science, Volume 394, Issue 6824.
- National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity. NIDDK.
- Harvard Health Publishing. (2025, updated 2026). A Guide to Weight-Loss Medications: Anti-obesity drugs, from older pills to the new GLP-1s. Harvard Health.
- Bergman, Jerry. How the Vagus Nerve Regulates Digestion. Creation-Evolution Headlines, November 18, 2025.
- Bergman, Jerry. Of All the Nerves, the Great Vagus Connects Everything. Creation-Evolution Headlines, September 1, 2026.
- Coppedge, David F. Pancreas Knows Not to Digest Itself. Creation-Evolution Headlines, April 24, 2022.
- Bergman, Jerry. Do Mutations Create New Genetic Information? Creation-Evolution Headlines, July 5, 2022.
- Fritz, Ronald D. Cells Have a ‘Hail Mary’ Strategy to Minimize Damage. Creation-Evolution Headlines, June 2, 2026.
- Fritz, Ronald D. “Design Crashes the LUCA Party.” Creation-Evolution Headlines, April 22, 2026.
Ronald D. Fritz, PhD, is a retired research statistician whose career spanned 27 years. Before entering the field of statistics, he worked as an engineer and engineering manager in the defense industry. He earned his doctorate in Industrial Engineering, with a minor in Mathematical Statistics, from Clemson University, where he was honored as a Dean’s Scholar.
Dr. Fritz served as a consulting statistician across a broad range of industries, culminating in a 12-year role as a global statistical resource at PepsiCo. During his time at PepsiCo, he led significant research on gluten contamination in oats and its relationship to celiac disease, publishing several articles on the subject.
In retirement, Dr. Fritz developed a deep interest in creation science, sparked by a visit to the Creation Museum in Petersburg, Kentucky. As he delved into the topic, he shared his findings with his pastor, which led to an invitation to speak at their church. This initial presentation opened the door to further speaking engagements at churches throughout the region.
Dr. Fritz has been married for 35 years to his wife, Mitzie. They live in the mountain community of Bee Log, North Carolina, within sight of the church where they were married and now worship. In his free time, Dr. Fritz tends a small chestnut orchard on their property, working to revive what was once a cherished local delicacy. The couple has two adult children.